Of note, we recently showed in preclinical studies that breast cancers harboring the ESR1 mutations remain sensitive to palbociclib.15 Overall survival data from multiple large, randomized, phase 3 studies evaluating the role of CDK4/6 inhibitors in ER-positive metastatic breast cancer are not yet mature. This evidence concerns the gene CDK4 and breast cancer.